According to The Center for Biosimilars, the U.S. Food and Drug Administration (FDA) has approved Celltrion Healthcare’s adalimumab-aaty (Yuflyma). The company explained that the new high-concentration, citrate-free medication is the ninth adalimumab biosimilar available and is indicated for patients with inflammatory diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa. Patients will have the option of administering the biosimilar through either a prefilled syringe or an autoinjector. Celltrion Healthcare noted that the medication will be available in July 2023.
June 02, 2023